DREADD: a chemogenetic GPCR signaling platform

Hu Zhu; Bryan L Roth

doi:10.1093/ijnp/pyu007

DREADD: a chemogenetic GPCR signaling platform

Int J Neuropsychopharmacol. 2014 Oct 31;18(1):pyu007. doi: 10.1093/ijnp/pyu007.

Authors

Hu Zhu¹, Bryan L Roth²

Affiliations

¹ Department of Pharmacology, University of North Carolina Chapel Hill Medical School, Chapel Hill, NC (Drs Zhu and Roth).
² Department of Pharmacology, University of North Carolina Chapel Hill Medical School, Chapel Hill, NC (Drs Zhu and Roth). [email protected].

Abstract

Recently, we created a family of engineered G protein-coupled receptors (GPCRs) called DREADD (designer receptors exclusively activated by designer drugs) which can precisely control three major GPCR signaling pathways (Gq, Gi, and Gs). DREADD technology has been successfully applied in a variety of in vivo studies to control GPCR signaling, and here we describe recent advances of DREADD technology and discuss its potential application in drug discovery, gene therapy, and tissue engineering.

Keywords: GPCRs; GsD; chemogenetics; hM3Dq; hM4Di.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Animals
Genetic Techniques*
Humans
Neurons / drug effects
Neurons / physiology
Receptors, G-Protein-Coupled / genetics*
Receptors, G-Protein-Coupled / metabolism*
Signal Transduction / physiology

Substances

Receptors, G-Protein-Coupled

Abstract

Publication types

MeSH terms

Substances

Grants and funding